Scientists Fine-Tune Clot-Busting drug for brain hemorrhage in the lab

NCT ID NCT07411079

Recruiting now Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses blood samples from over 1,100 people to create artificial clots in the lab, mimicking brain hemorrhages. Researchers test a modified clot-busting drug (rtPA) to find the best dose for different bleeding risks. The goal is to improve clot removal and guide future treatments for this serious condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: modified tissue plasminogen activator (rtPA)
What this could lead to: If successful, this could lead to personalized dosing of clot-busting drugs for brain hemorrhage patients, potentially improving clot removal and reducing disability.
What could go wrong: This is an early lab study using artificial clots, not real patients. Results may not translate to actual treatment, and the drug's safety and effectiveness in people remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEEDING DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemorrhagic disease intracerebral hemorrhage Intracranial Hemorrhages vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEEDING DISORDERS HEMORRHAGIC RISK CONDITIONS INTRACEREBRAL HEMORRHAGE

Contacts and locations

Locations

CHU de Lille
RECRUITING

Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.